The QIBA FDG-PET/CT Biomarker Committee: An Overview and Status Update

Accelerating the development of new therapies and improving assessment of response

PET/CT Innovation & Quantitation

Quantitation – Why and How

- Why Quantification?
  - Increase the Utility and Value of Imaging
  - Improve individual patient care
  - Clinically proven detection and longitudinal quantitation for follow-up
  - Moving imaging from diagnostics and staging to therapy assessment

QIBA Profiles: Guidance for All Aspects of Quantitation

- QIBA Profiles
  - Guidance for All Aspects of Quantitation
  - Reports and Data Set
    - Analyzing technical and sources of errors, registration performance, or phantoms and synthetic data
    - Clinical performance is terms of entity and inter-rater variability
    - Clinical utility

QIBA PET/CT Projects

- Ongoing Activities 2015-2016
  - Specific accomplishments and plan
    - Collection of recommendations for quantitative PET
    - Prototype software based with RMI to FDA for Biomarker Status
    - QIBA grant applications to fund operations
    - Year 1-4 research projects accomplished
    - Year 5 research project funding progress
    - FDG-PET/CT Profile published and publicly reviewed
    - Collaboration with IPEM on Protocols
    - Awarded writing group rotation II agent development project
    - FDG-PET/CT Profile (in progress)
    - FDG-PET/CT Profile (in progress)
    - Complete Phase 4 of proficiency testing of FDG-PET/CT profiles
    - Implementation of Protocols
    - Clinical use of Profile

BIOMARKERS

- New molecular diagnostic agents
  - New tests for existing agents

QIBA Profiles

- Biomarkers To Quantify Hallmarks of Cancer
  - Characterize Hallmarks of Disease and Response to Therapy

FDG PET/CT Profile Field Test

- The potential for widespread deployment of the profile was assessed as part of a clinical feasibility study that evaluated the impact of the profile and the patient’s recommendations

For more information, visit http://qibawiki.rsna.org

Various QIBA projects and activities have been funded in whole or in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Service, under Contracts No. HHSN268201000050C, No. HHSN268201300071C.